MALVERN, Pa.--(BUSINESS WIRE)--Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic and inflammatory diseases, announced today the publication of collaborative research in the Journal of Allergy and Clinical Immunology entitled, “Serum amyloid P attenuates M2 macrophage activation and protects against fungal spore–induced allergic airway disease.” The research showed that human Pentraxin-2 protein (PTX-2, also called human SAP), a pentraxin therapeutic compound, potently inhibits M2 macrophage differentiation and represents a novel therapeutic approach for the treatment of asthma. This builds on the body of research showing PTX-2/SAP’s unique role in regulating a fundamental mechanism of the innate immune system and activating the body’s natural ability to resolve tissue damage in disease processes that cause fibrosis and inflammation.
